Elevation of pulmonary CD163+ and CD204+ macrophages is associated with the clinical course of idiopathic pulmonary fibrosis patients
Authors:
- 1 September 2019
- journal article
- research article
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 11 (9) , 4005-4017
Abstract
Background: M2-like/repair macrophages are thought to contribute to fibrotic process of idiopathic pulmonary fibrosis (IPF). We analyzed the association between pulmonary accumulation of M2-like macrophages and survival in IPF patients. Methods: Lung tissues were obtained by surgical lung biopsy from patients with IPF (n=16), nonspecific interstitial pneumonia (NSIP, n=8) and control subjects (n=14). Samples were also obtained at autopsy from 9 patients who died of acute exacerbation (AE) of IPF. Lung specimens and/or human peripheral blood mononuclear cells-derived macrophages were evaluated by immunohistochemistry for expression of CD68 (pan-macrophage marker), CD163, and CD204 (M2-like macrophage markers), and by in situ mRNA hybridization and ELISA for production of transforming growth factor-β1 (TGF-β1). Results: CD68+, CD163+, and CD204+ cell counts and CD163+/CD68+ and CD204+/CD68+ cell ratios were comparable in IPF and NSIP lung tissues and significantly higher than in control tissues. IPF-AE lung samples contained significantly elevated CD68+ and CD163+ cell counts and CD163+/CD68+ cell ratio compared with IPF samples, whereas CD204+ cell counts and CD204+/CD68+ cells ratio did not differ. High CD163+/CD68+ and CD204+/CD68+ cell ratios were significantly associated with shorter overall survival and time-to-AE in IPF patients. In vitro-differentiated human CD163+ and CD204+ macrophages both secreted TGF-β1; however, the novel IPF drug pentraxin 2/serum amyloid protein could suppress secretion only by CD204+ macrophages. Conclusions: Pulmonary accumulation of CD163+ and CD204+ macrophages is associated with worse clinical course in IPF patients. Suppression of macrophage activation and TGF-β1 secretion may be a potential therapeutic target for IPF.Keywords
This publication has 51 references indexed in Scilit:
- Macrophages in Tissue Repair, Regeneration, and FibrosisImmunity, 2016
- Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and CHepatology, 2014
- Utility of KL-6/MUC1 in the clinical management of interstitial lung diseasesRespiratory Investigation, 2012
- Suppression of TLR4-mediated inflammatory response by macrophage class A scavenger receptor (CD204)Biochemical and Biophysical Research Communications, 2011
- TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid PThe International Journal of Biochemistry & Cell Biology, 2011
- Alternative Activation of Macrophages: Mechanism and FunctionsImmunity, 2010
- TGF-β and fibrosis in different organs — molecular pathway imprintsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomasThe Journal of Pathology, 2008
- The macrophage scavenger receptor CD163Immunobiology, 2005
- C‐C chemokine receptor 2 (CCR2) deficiency improves bleomycin‐induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage‐derived matrix metalloproteinasesThe Journal of Pathology, 2004